Recent Advances in Treating Endometrial and Cervical Cancers - Episode 12

Recent Updates in NCCN Guidelines for the Treatment of Recurrent or Metastatic Cervical Cancer

December 27, 2023

Bradley Monk, MD, Dana M. Chase, MD, FACOG, David O'Malley, MD, Leslie M. Randall, MD, Thomas C. Krivak, MD

Leslie M. Randall, MD, reviews updates to the NCCN guidelines for cervical cancer, including the use of pembrolizumab in the second and third-line settings, the results of the KEYNOTE-826 trial, and the potential role of induction chemotherapy with weekly carboplatin and paclitaxel in the treatment of locally advanced cervical cancer.

EP. 1: Diagnosing and Staging Patients With Endometrial Cancer

EP. 2: Updated NCCN Guidelines for the Treatment of Advanced or Recurrent Endometrial Cancer

EP. 3: Shared Decision-Making in Advanced or Recurrent Endometrial Cancer

EP. 4: The Role of dMMR in the Progression of Endometrial Cancer

EP. 5: Dostarlimab Plus Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Cancer: Data from the RUBY Trial

EP. 6: The NRG-GY018 Trial: Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer

EP. 7: Emerging Data on Combination Therapies in Advanced or Recurrent Endometrial Cancer

EP. 8: Advances in Anti-HER2 ADCs in Patients With Advanced or Recurrent Endometrial Cancer

EP. 9: Recent Data on Anti-TROP2 ADCs for Patients With Advanced or Recurrent Endometrial Cancer

EP. 10: Future Directions in the Treatment of Advanced or Recurrent Endometrial Cancer

EP. 11: Staging and Biomarker Testing For Patients With Cervical Cancer

Now Viewing